News | May 13, 2013

First Patient Enrolled in Study Evaluating the Multi-Electrode nMARQ Pulmonary Vein Isolation System

System may aid treatment of paroxysmal atrial fibrillation

BioSense Webster eMARQable Clinical Study nMARQ System Atrial Fibrillation

May 13, 2013 — Biosense Webster Inc. announced the first patient has been enrolled in the reMARQable clinical study. ReMARQable will assess the safety and efficacy of the use of the nMARQ Pulmonary Vein Isolation System to treat paroxysmal atrial fibrillation. Atrial fibrillation (Afib) is a heart rhythm disorder that affects approximately 20 million people worldwide.

Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center was first facility in the United States to use the nMARQ System to treat paroxysmal Afib as part of the clinical study. Andrea Natale, M.D., FHRS, FACC, FESC, cardiac electrophysiologist and executive medical director of TCAI, performed the first case in the United States, and was among the first to use this new catheter in Europe. “I am encouraged by the possibilities of this new system,” said Natale. “This technology could provide another tool to more effectively treat patients with paroxysmal Afib.”

“We are excited about the start of the pivotal U.S. clinical trial for this innovative new technology,” said Shlomi Nachman, worldwide president, Biosense Webster, Inc. “By combining the multi-ablation capability of nMARQ System with the proven irrigation technology and the unparalleled mapping accuracy of the CARTO 3 System, this new platform has been designed to reduce procedure time and complexity.”

The nMARQ System consists of a multi-electrode, irrigated catheter ablation system. Each nMARQ Catheter has 10 irrigation holes per electrode completely surrounding the electrodes. The reMARQable trial will enroll approximately 400 patients at up to 50 sites in the U.S. The study is being conducted under a U.S. Food and Drug Administration (FDA)-approved Investigational Device Exemption, and the new catheter is not available in the United States outside of the reMARQable study. Further information is available at: http://clinicaltrials.gov/ct2/show/NCT01824394?term=remarqable&rank=1.

For more information: www.biosensewebster.com

Related Content

Smartphone Apps Help Patients and Providers Manage Atrial Fibrillation
News | Patient Engagement| October 19, 2017
October 19, 2017 — Novel smartphone and tablet applications for atrial fibrillation patients and healthcare professio
The Respicardia Remede System is a pacemaker-like device designed to improve cardiovascular health by restoring natural breathing during sleep in patients with Central sleep apnea.
Technology | Heart Failure| October 18, 2017
October 18, 2017 — The U.S.
Baylis Medical and Siemens Co-Sponsor Transseptal Access Training Course
News | EP Lab| October 18, 2017
Baylis Medical Co. Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at...
CardioFocus Announces European CE Mark Approval of HeartLight Excalibur Balloon
Technology | Ablation Systems| October 10, 2017
October 10, 2017 — CardioFocus Inc. recently announced the European CE Mark approval of the HeartLight Excalibur Ball
The Apama Radiofrequency (RF) Balloon Catheter System.
News | Ablation Systems| October 02, 2017
October 2, 2017 — Boston Scientific announced a definitive agreement to acquire Apama Medical Inc., a privately-held
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Spectranetics Initiates Class I Recall for Bridge Occlusion Balloon Catheter
News | EP Lab| September 27, 2017
Spectranetics is recalling its Bridge Occlusion Balloon Catheter due to the possibility of a blocked guidewire lumen in...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Overlay Init